Skip to main content

Table 2 Baseline clinical characteristics of LN patients stratified by crescent

From: Role of crescents for lupus nephritis in clinical, pathological and prognosis: a single-center retrospective cohort study

 

Non-crescent

Crescent

P value

Number of patients

146

150

 

Gender = male, n (%)

19 (13.0)

23 (15.3)

0.619

Age (year) (mean (S.D.))

31.93 (10.16)

31.93 (10.86)

0.997

BMI (mean (S.D.))

21.69 (2.93)

21.95 (2.86)

0.429

MBP (mmHg) (mean (S.D.))

97.98 (17.01)

105.38 (16.15)

 < 0.001

Serum creatinine (μmol/L) (median [IQR])

52.38 [46.21, 63.75]

69.09 [55.62, 90.63]

 < 0.001

eGFR (median [IQR])

122.88 [111.63, 131.53]

105.91 [76.42, 125.30]

 < 0.001

Serum albumin (g/L) (median [IQR])

28.30 [23.13, 33.74]

25.43 [21.94, 28.81]

0.001

WBC count (10^9/L) (median [IQR])

6.80 [5.12, 8.86]

7.87 [6.16, 9.67]

0.019

Hemoglobin (g/L) (median [IQR])

110.02 [96.38, 121.15]

98.70 [84.72, 111.08]

 < 0.001

Platelet (10^9/L) (median [IQR])

183.50 [159.33, 233.25]

181.50 [142.00, 226.67]

0.413

Proteinuria (g/24-h) (median [IQR])

2.08 [0.96, 4.10]

3.52 [2.02, 5.91]

 < 0.001

Urinary albumin/creatinine ratio (mg/μmol) (median [IQR])

0.22 [0.11, 0.44]

0.40 [0.22, 0.61]

 < 0.001

Urine WBC (/HP) (median [IQR])

2.08 [1.12, 5.50]

6.51 [3.60, 11.35]

 < 0.001

Urine RBC (/HP) (median [IQR])

24.83 [8.22, 38.20]

37.90 [19.60, 72.14]

 < 0.001

C3 (g/L) (median [IQR])

0.48 [0.36, 0.69]

0.43 [0.35, 0.54]

0.007

C4 (g/L) (median [IQR])

0.10 [0.05, 0.14]

0.07 [0.05, 0.11]

0.015

Positive ANA, n (%)

91 (62.3)

109 (72.7)

0.063

Positive anti-cardiolipin, n (%)

1 (0.7)

3 (2.0)

0.623

Positive anti-dsDNA, n (%)

51 (34.9)

88 (58.7)

 < 0.001

Positive anti-Ro52, n (%)

17 (11.6)

30 (20.0)

0.057

Positive anti-Sm, n (%)

33 (22.6)

38 (25.3)

0.590

Positive anti-ssA, n (%)

79 (54.1)

80 (53.3)

0.908

Positive anti-ssB, n (%)

28 (19.2)

22 (14.7)

0.353

Positive anti-u1RNP, n (%)

53 (36.3)

62 (41.3)

0.405

Lupus anticoagulant ratio (median [IQR])

1.10 [0.99, 1.25]

1.00 [0.84, 1.15]

 < 0.001

SLEDAI(median [IQR])

16.00 [11.00, 19.00]

18.00 [15.00, 22.00]

 < 0.001

Follow-up month (median [IQR])

57.00 [30.50, 96.50]

38.50 [19.00, 66.75]

 < 0.001

  1. BMI body mass index, MBP mean blood pressure, eGFR estimated glomerular filtration rate, WBC white blood cells, RBC red blood cells, C3 complement factor 3, C4 complement factor 4, ANA antinuclear antibodies, dS.D.NA double-stranded DNA, ssA Sjögren’s-syndrome-related antigen A; ssB, Sjögren’s-syndrome-related antigen B; u1RNP, U1 ribonucleoprotein; SLEDAI, systemic lupus erythematosus disease activity index, S.D, standard deviation, IQR, interquartile range
Back to article page

European Journal of Medical Research

ISSN: 2047-783X

Contact us